The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

Area of Science:

• Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a significant healthcare-associated pathogen, increasingly prevalent in community settings.
• Vancomycin, a primary glycopeptide antibiotic for MRSA, faces challenges due to the emergence of vancomycin-intermediate (VISA) and vancomycin-resistant (VRSA) strains.
• Mechanisms of vancomycin resistance, potentially involving bacterial cell wall alterations and genetic transfer, are under investigation.

Purpose of the Study:

• To highlight the growing concern of MRSA, VISA, and VRSA infections.
• To underscore the limitations in current detection methods and screening programs.
• To emphasize the urgent need for novel antimicrobial agents effective against resistant MRSA strains.

Main Methods:

• Review of current literature on MRSA, VISA, and VRSA epidemiology and resistance mechanisms.
• Analysis of risk factors associated with VRSA development.
• Assessment of current screening and detection methodologies for MRSA, VISA, and VRSA.

Main Results:

• MRSA is spreading from healthcare settings to the community.
• Emergence of VISA and VRSA strains significantly limits treatment options.
• Risk factors for VRSA include advanced age, peripheral vascular disease, and chronic ulcers.
• Underdetection of VISA/VRSA is likely due to suboptimal screening and detection limitations.

Conclusions:

• The increasing prevalence of MRSA, VISA, and VRSA poses a serious threat to public health.
• Enhanced screening protocols targeting high-risk patients are crucial.
• Development of new antimicrobial classes is urgently required to combat these resistant infections.